Lynn Anne Bristol

Array ( [id] => 16742091 [patent_doc_number] => 10967060 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Synergistic combination of immunologic inhibitors for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/031650 [patent_app_country] => US [patent_app_date] => 2018-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 21 [patent_no_of_words] => 38878 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16031650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17029749 [patent_doc_number] => 11091554 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => Binding molecules specific for HER3 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/024391 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 67 [patent_no_of_words] => 48126 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16024391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343620 [patent_doc_number] => 20200308270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => STABILIZED CHIMERIC FABS [patent_app_type] => utility [patent_app_number] => 16/624479 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14214657 [patent_doc_number] => 20190119713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY [patent_app_type] => utility [patent_app_number] => 16/018400 [patent_app_country] => US [patent_app_date] => 2018-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23248 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16018400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336075 [patent_doc_number] => 20220002406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF [patent_app_type] => utility [patent_app_number] => 16/615122 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13833 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16087093 [patent_doc_number] => 20200197533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => COMBINATION CANCER THERAPY USING CHIMERIC ANTIGEN RECEPTOR ENGINEERED NATURAL KILLER CELLS AS CHEMOTHERAPEUTIC DRUG CARRIERS [patent_app_type] => utility [patent_app_number] => 16/609443 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16609443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622221 [patent_doc_number] => 20180362662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => ANTI-HER2 GLYCOANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/014255 [patent_app_country] => US [patent_app_date] => 2018-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590805 [patent_doc_number] => 20180346951 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES [patent_app_type] => utility [patent_app_number] => 16/007590 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650009 [patent_doc_number] => 10927172 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Caninized murine antibodies to human PD-1 [patent_app_type] => utility [patent_app_number] => 16/007077 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14729 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185250 [patent_doc_number] => 20210332135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => GUIDED COMBINATIONAL THERAPEUTIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/619769 [patent_app_country] => US [patent_app_date] => 2018-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16619769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590113 [patent_doc_number] => 20180346605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => Engineered Multispecific Antibodies and Other Multimeric Proteins with Asymmetrical CH2-CH3 Region Mutations [patent_app_type] => utility [patent_app_number] => 15/997222 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19457723 [patent_doc_number] => 12098203 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA [patent_app_type] => utility [patent_app_number] => 16/608555 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 15 [patent_no_of_words] => 17790 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 523 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13428101 [patent_doc_number] => 20180265593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR ROR1 [patent_app_type] => utility [patent_app_number] => 15/997635 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60068 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590021 [patent_doc_number] => 20180346559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => ANTI-CANCER COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 15/995375 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15995375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618821 [patent_doc_number] => 20180360962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => COMBINATION OF DR5 AGONIST AND ANTI-PD-1 ANTAGONIST AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/993687 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15993687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17111813 [patent_doc_number] => 20210292410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT [patent_app_type] => utility [patent_app_number] => 16/615953 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586639 [patent_doc_number] => 20180344868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 15/992345 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15992345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072349 [patent_doc_number] => 20190085062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS [patent_app_type] => utility [patent_app_number] => 15/989860 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15989860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13444179 [patent_doc_number] => 20180273632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/986565 [patent_app_country] => US [patent_app_date] => 2018-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 4 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15986565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18853940 [patent_doc_number] => 11851502 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-26 [patent_title] => Production of T cell retargeting hetero-dimeric immunoglobulins [patent_app_type] => utility [patent_app_number] => 15/984822 [patent_app_country] => US [patent_app_date] => 2018-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 79 [patent_no_of_words] => 48046 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 259 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15984822 [rel_patent_id] =>[rel_patent_doc_number] =>)